Synthesis, Characterization and Biological Evaluation of Novel 1- Substituted-4-(2-methoxyphenyl)-s-triazolo[4,3-a]quinazolin-5(4H)-ones by M Gobinath et al.
642   International Journal of Drug Design and Discovery    Volume 2 • Issue 4 • October – December 2011 
Synthesis, Characterization and Biological Evaluation of Novel 1- 
Substituted-4-(2-methoxyphenyl)-s-triazolo[4,3-a]quinazolin-5(4H)-ones 
M. Gobinath1, N. Subramanian2*, K. Ruckmani2, V. Alagarsamy3  
1Department of Pharmaceutical Engineering & Technology, Bharathidasan University, Tiruchirappalli - 620 024, India. 
2Department of Pharmaceutical Technology, Anna University of Technology Tiruchirappalli, Tiruchirappalli - 620 024, India. 
3Medicinal Chemistry Research Laboratory, MNR College of Pharmacy, Sangareddy, Gr. Hyderabad-502 294, India. 
ABSTRACT: In the present study a series of 1-substituted-4-(2-methoxyphenyl)-s-triazolo[4,3-a]quinazolin-5(4H)-ones 
were synthesized and are screened for their H1-antihistaminic activity. The synthesized compounds were characterized by 
IR, 1H-NMR and mass spectral data; the purity of the compounds was determined by elemental analysis. Antihistaminic 
activity of the title compounds was evaluated by histamine induced bronchoconstriction method in guinea pigs. Among the 
series, 4-(2-methoxyphenyl)-1-methyl[1,2,4] triazolo[4,3-a]quinazolin-5(4H)-one (5) was the most potent with the percentage 
protection of 68.67% and its potency is comparable to that of standard chlorpheniramine maleate (percentage protection 
71.00). Interestingly the sedative property of compound 5 was found to be negligible (7.4%) when compared to 
chlorpheneramine maleate (35.4%). 
KEYWORDS: Antihistaminic activity; quinazolin-5-ones; histamine; bronchoconstriction. 
Introduction 
Heterocyclic synthesis has emerged as powerful technique 
for generating new chemical entities useful for drug 
discovery1. Heterocyclic compounds provide scaffolds on 
which pharmacophores can be arranged to obtain potent 
and selective drugs2. The first generation anti-histamines 
penetrate the blood brain barrier and also possess 
anticholinergic properties and this has led to the 
development of a second generation H1-antagonists such as 
terfenadine, cetirizine and astemizole3. A common feature 
of first generation compounds includes two aryl or 
heteroaryl rings linked to an aliphatic tertiary amine via the 
side chain (e.g. diphenhydramine and pheniramine)4, the 
second-generation compounds (terfenadine and cetirizine) 
also contain many of the structural features of first 
generation compounds. The real breakthrough of non-
sedative antihistamines came in the early eighties of 
twentieth century when the discovery of modern 
antihistamines, was found to exhibit potent antihistaminic 
activity without sleep-inducing effect5. Condensed 
heterocycles containing new generation of H1-
antihistamines (e.g. loratadine, azelastine and flazelastine) 
that does not possess the above mentioned pharmacophore 
for H1-antihistamines gave way for the discovery of many 
novel antihistamines temelastine and mangostin6,7. 
Quinazolinones are associated with a wide range of 
biological and pharmacological activities such as 
analgesic8, anti-inflammatory9, antifungal10,11, antiviral12 
and antihistaminic activities13,14. In this continuation we 
demonstrated that the quinazoline derivatives as potent 
antihistamines with least sedation15,16. The present work is 
an extension of our ongoing efforts towards the 
development and identification of new quinazolinone 
derived antihistaminics; thus we aimed to synthesize a 
series of 1-substituted-4-(2-methoxyphenyl)-s-triazolo[4,3-
a]quinazolin-5(4H)-ones. The synthesized compounds 
were tested for their in vivo H1-antihistaminic activity on 
conscious guinea pigs. As sedation is one of the major side 
effects associated with antihistamines, the test compounds 
were also evaluated for their sedative potentials, by 
measuring the reduction in locomotor activity using 
actophotometer. 
Materials 
Starting material for the synthesis, reagents and solvents 
were of analytical grade and were purchased from Aldrich 
Chemical Co., Merck Chemical Co. and dried when 
necessary. Histamine (Sigma Chemicals, USA), 
Aminophylline (Unichem, Mumbai), Chlorpheniramine 
maleate (Hoechst, Mumbai), Cetirizine (Sun Pharma, 
Mumbai) were procured for the present biological study. 
All melting points reported were taken on Veego make 
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Silicone oil bath-type melting point apparatus and are 
uncorrected. NMR spectra (on Varian 300 MHz) were 
recorded in CDCl3 (unless specified) with TMS as internal 
reference (chemical shift in δ, ppm), IR spectra (Shimadzu 
FT-IR, 8300) in KBr (ν max in cm-1) and Mass spectra at 
70 eV on a MASPEC msw 9629 instrument. Elemental 
analysis was performed in Carlo erba. Silica gel G (E. 
Merck) was used for TLC and iodine vapours used for 
exposure of TLC plates. Anhydrous sodium sulphate (S.D. 
fine chemicals) was used as drying agent. 
Experimental 
Synthesis of 3-(2-methoxyphenyl)-2-thioxo-2,3-dihydro-
1H-quinazolin-4-one (1)  
A solution of 2-methoxy aniline (0.02 mole) in dimethyl 
sulphoxide (10 ml) was stirred vigorously. To this was 
added carbon disulphide (1.6 ml; 0.026 mole) and aqueous 
sodium hydroxide 1.2 ml (20 molar solution) drop wise 
during 30 minutes with stirring. Dimethyl sulphate (0.02 
mole) was added gradually keeping the reaction mixture 
stirring in freezing mixture for 2 hours. The reaction 
mixture was then poured into ice water. The solid obtained 
was filtered, washed with water, dried and recrystallized 
from ethanol. Methyl anthranilate (0.01 mole) and the 
above prepared N-(2-methoxyphenyl)-methyl dithio- 
carbamic acid (0.01 mole), were dissolved in ethanol (20 
ml). To this anhydrous potassium carbonate (100 mg) was 
added and refluxed for 19 hours. The reaction mixture was 
cooled in ice and the solid separated was filtered and 
purified by dissolving in 10% alcoholic sodium hydroxide 
solution and re-precipitated by treating with dilute 
hydrochloric acid. The solid obtained was filtered, washed 
with water, dried and recrystallized from ethanol. Yield = 
83%, melting point 293°C-295°C, IR (KBr): 3217 (NH), 
1659 (C=O), 1231 (C=S)  cm-1, 1H NMR (500 MHz, 
CDCl3): δ 3.89 (s, 3H, OCH3), 7.07-8.19 (m, 8H, Ar-H), 
10.26 (br s, 1H, NH), Mass (m/z): 284 [M+], Analysis 
Calculated for C15H12N2O2S: C, 63.36; H, 4.25; N, 9.85. 




zolin-4-one (1) (0.01 mole) was dissolved in 40 ml of 2% 
alcoholic sodium hydroxide solution. To this dimethyl 
sulphate (0.01 mole) was added drop wise with stirring. 
The stirring was continued for 1 hour, the reaction mixture 
was then poured into ice water. The solid obtained was 
filtered, washed with water, dried and recrystallized from 
ethanol:chloroform (75:25) mixture. Yield: 82 %, melting 
point: 146°C-148°C, IR (KBr): 1682 (C=O), 1605 (C=N) 
cm-1, 1H NMR (500 MHz, CDCl3): δ 2.55 (s, 3H, SCH3), 
3.90 (s, 3H, OCH3), 7.06-8.28 (m, 8H, Ar-H), Mass (m/z): 
298 [M+]; Analysis Calculated for C16H14N2O2S: C, 64.41; 




zolin-4-one (2) (0.01 mole) was dissolved in ethanol (25 
ml). To this hydrazine hydrate (99%) (0.1 mole) and 
anhydrous potassium carbonate (100 mg) was added and 
refluxed for 23 hours. The reaction mixture was cooled and 
poured into ice water. The solid so obtained was filtered, 
washed with water, dried and recrystallized from 
chloroform-benzene (25:75) mixture. Yield.77 %, melting 
point 203°C-205°C, IR (KBr): 3313, 3226 (NHNH2), 1684 
(C=O) cm-1, 1H NMR (500 MHz, CDCl3): δ 2.37 (s, 3H, 
OCH3), 4.65 (br s, 2H, NH2), 7.19-8.12 (m, 8H, Ar H), 
8.52 (br s, 1H, NH), Mass (m/z): 282 [M+]; Analysis 
Calculated for C15H14N4O2: C, 63.82; H, 4.99; N, 19.84. 
Found: C, 63.79; H, 4.98; N, 19.83. 
Synthesis of 4-(2-methoxyphenyl)-4H-[1,2,4] triazolo 
[4,3-a] quinazolin-5-one (4) 
The 2-hydrazino-3-(2-methoxyphenyl)-3H-quinazolin-4-
one (3) (0.01 mole) and formic acid (25 ml) was taken in a 
round bottomed flask and refluxed for 30 h, cooled and 
poured into ice water. The solid obtained was filtered, 
washed with water, dried and recrystallized from ethanol. 
Yield: 89 %, mp. 251-253 °C, IR (KBr): 1645 (C=O), 1621 
(C=N) cm-1, 1H NMR (500 MHz, CDCl3): δ 3.88 (s, 3H, 
OCH3), 7.23-8.27 (m, 8H, Ar-H), 9.11 (s, 1H, Ar-H), Mass 
(m/z): 292 [M+]; Anal. Calcd. for C16H12N4O2: C, 65.75; H, 
04.14; N, 19.17. Found: C, 65.80; H, 4.16; N, 19.14.  
Synthesis of 4-(2-methoxyphenyl)-1-methyl-4H-[1,2,4] 
triazolo [4,3-a] quinazolin-5-one (5) 
The 2-hydrazino-3-(2-methoxy phenyl) quinazolin-4(3H)-
one (0.01 mole) and acetic acid (15 ml) was taken in a 
round bottom flask and refluxed for 30 hours, cooled and 
poured into ice water. The solid obtained was filtered, 
washed with water, dried and recrystallized from ethanol. 
Yield. 85 %, melting point 241°C-242°C, IR (KBr): 1681 
(C=O), 1602 (C=N) cm-1,1H NMR (500 MHz, CDCl3) : δ 
2.45 (s, 3H, CH3), 3.93 (s, 3H, OCH3), 7.13-8.48 (m, 8H, 
Ar-H),Mass (m/z) : 306 [M+], Analysis Calculated for 
C17H14N4O2:  C, 66.66; H, 04.61; N, 18.29. Found: C, 
66.68; H, 4.62; N, 18.33. 
Synthesis of 1-ethyl-4-(2-methoxyphenyl)-4H-[1,2,4] 
triazolo [4,3-a] quinazolin-5-one (6) 
The 2-hydrazino-3-(2-methoxy phenyl) quinazolin-4(3H)-
one (0.01 mole) and propionic acid (15 ml) were taken in a 
round bottom flask and refluxed for 26 hours, cooled and 
poured into ice water. The solid obtained was filtered, 
washed with water, dried and recrystallized from ethanol. 
Yield. 80 %, melting point 284°C-285°C, IR (KBr): 1682 
(C=O), 1605 (C=N) cm-1, 1H NMR (500 MHz, CDCl3): δ 
1.33-1.36 (t, 3H, CH3), 2.72-2.77 (q, 2H, CH2), 3.92 (s, 
3H, OCH3), 7.12-8.46 (m, 8H, Ar-H), Mass (m/z): 320 
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[M+], Analysis Calculated for C18H16N4O2:  C, 67.49; H, 
05.03; N, 17.49. Found: C, 67.52; H, 5.04; N, 17.48. 
Synthesis of 4-(2-methoxyphenyl)-1-propyl-4H-[1,2,4] 
triazolo [4,3-a] quinazolin-5-one (7) 
The 2-hydrazino-3-(2-methoxy phenyl) quinazolin-4(3H)-
one (0.01 mole) and butyric acid (15 ml) was taken in a 
round bottom flask and refluxed for 23 hours, cooled and 
poured into ice water. The solid obtained was filtered, 
washed with water, dried and recrystallized from ethanol. 
Yield. 80 %, melting point 271°C-273°C, IR (KBr): 1682 
(C=O), 1603 (C=N) cm-1, 1H NMR (500 MHz, CDCl3): δ 
0.96-0.99 (t, 3H, CH3), 1.75-1.79 (t, 2H, CH2), 2.68-2.71 
(m, 2H, CH2), 3.91 (s, 3H, OCH3), 7.11-8.46 (m, 8H, Ar-
H), Mass (m/z): 334 [M+], Analysis Calculated for 
C19H18N4O2: C, 68.25; H, 05.43; N, 16.76. Found: C, 
68.28; H, 05.46; N, 16.74. 
Synthesis of 1-chloromethyl-4-(2-methoxyphenyl)-4H-
[1,2,4] triazolo [4,3-a] quinazolin-5-one (8)  
The 2-hydrazino-3-(2-methoxy phenyl) quinazolin-4(3H)-
one (0.01 mole) and chloroacetyl chloride (0.01 mole) in 
glacial acetic acid (15 ml) was taken in a round bottom 
flask and refluxed for 13 hours, cooled and poured into ice 
water. The solid obtained was filtered, washed with water, 
dried and recrystallized from chloroform-ethanol (75:25) 
mixture. Yield: 81 %,  melting point 282°C-283°C, IR 
(KBr): 1697 (C=O), 1607 (C=N) cm-1,1H NMR (500 MHz, 
CDCl3): δ 3.62 (s, 3H, OCH3), 3.85 (s, 2H, CH2), 7.28-8.48 
(m, 8H, Ar-H), Mass (m/z): 340 [M+], 342 [M++2], 
Analysis Calculated for C17H13N4O2Cl: C, 59.92; H, 03.84; 
N, 16.44. Found: C, 59.88; H, 03.82; N, 16.45. 
Pharmacology 
The synthesized compounds were evaluated for 
antihistaminic and sedative-hypnotic activities. The 
animals were maintained in colony cages at 25°C ± 2°C, 
relative humidity of 45-55%, under a 12h light and dark 
cycle; they were fed standard animal feed. All the animals 
were acclimatized for a week before use. The Institutional 
Animal Ethics committee approved the protocol adopted 
for the experimentation of animals. 
Antihistaminic activity  
A modification of the technique of Van Arman was 
adopted to determine the antihistaminic potential of the 
synthesized compounds18. Male Dunkin Hartley Guinea 
pigs (250-300 g) were fasted for 12 hours. Six animals 
were taken in each group. The test compounds, was 
administered orally at a dose of 10 mg/Kg in 1% CMC and 
challenged with histamine aerosol (0.2% aqueous solution 
of histamine acid chloride 3 ml) in a vaponephrin pocket 
nebulizer sprayed into a closed transparent cage. The 
respiratory status reflecting the increasing degree of 
bronchoconstriction was recorded. The time for onset of 
convulsions (preconvulsion) was recorded. Animals 
remaining stable for more than 6 minutes were considered 
protected against histamine-induced bronchospasm. An 
intraperitoneal injection of chlorpheniramine maleate         
(Hoechst, Mumbai, India) at a dose of 25 mg/Kg was given 
for the recovery of the test animals. The mean 
preconvulsion time of animals, treated with the test 
compounds was compared to control and is expressed in 
terms of percentage protection (Table 1).  
 Percent protection = [1- (T1 / T2)] × 100 
  T2-preconvulsive time of test compound; T1- 
preconvulsive time of control. 
 The activity of the test compounds was compared with 
the standard antihistamine chlorpheniramine maleate.  
Sedative-hypnotic activity  
Sedative potential of the test compounds was determined 
by measuring the reduction in locomotor activity using 
actophotometer19,20. Swiss albino mice were chosen as test 
animals in a group of 6. Basal activity score was taken and 
then compounds 4-8 and standard chlorpheniramine 
maleate were administered orally at the dose of 5 mg/kg in 
1% CMC. Scores were recorded at 1, 2 and 3 hours after 
the drug administration. Student-t-test was performed to 
ascertain the significance of the exhibited activity. The 
percent reduction in loco motor activity was calculated by 
the following formula and shown in Table 2. 
% Reduction in motor activity = [(A-B)/A] × 100  
 Where A-basal score, B-score after drug treatment.  
Statistical analysis 
Statistical analysis of the biological activity of the test 
compounds on various animals was performed by one way 
anova followed by dunett test (manually). In all cases 
significance level of the means of individual groups were 
performed and compared with control. A significance level 
of p < 0.5 denoted significance in all cases. 
Results and discussion 
Chemistry 
The key intermediate 3-(2-methoxyphenyl)-2-thioxo-2,3-
dihydro-1H-quinazolin-4-one (1), was prepared by reacting 
2-methoxy aniline with carbon disulphide and sodium 
hydroxide in dimethyl sulphoxide to give sodium 
dithiocarbamate, which was methylated with dimethyl 
sulfate to afford the dithiocarbamic acid methyl ester, 
which upon reflux with methyl anthranilate in ethanol 
yielded the desired 3-(2-methoxyphenyl)-2-thioxo-2,3-
dihydro-1H-quinazolin-4-one (1) via the thiourea 
intermediate in good yield (83 %). The product obtained 
was cyclic and not an open chain thiourea. The 3-(3-
methoxyphenyl)-2-methylsulfanyl-3H-quinazolin-4-one 2 
was obtained by dissolving 1 in 2% alcoholic sodium 
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hydroxide solution and methylating with dimethyl sulphate 
with stirring at room temperature. Nucleophilic 
displacement of methylthio group of 2 with hydrazine 
hydrate was carried out using ethanol as solvent to afford 
2-hydrazino-3-(2-methoxyphenyl)-3H-quinazolin-4-one 3. 
The long duration of reaction (23 hours) required might be 
due to the presence of bulky aromatic ring at position 3, 
which might have reduced the reactivity of quinazoline 
ring system at C-2 position. The title compounds 4-8 were 
obtained in fair to good yields through the cyclization of 3 
with a variety of one carbon donors such as formic acid, 
acetic acid, propionic acid, butyric acid and chloroacetyl 
chloride at reflux. The 1H NMR spectrum of 4-8 showed 
the absence of NH and NH2 signals. All the synthesized 
compounds were confirmed by spectral data (IR, NMR and 
mass spectra). Elemental (C, H, N) analysis satisfactorily 
confirmed elemental composition and purity of the 




























































Fig. 1  Synthetic protocol of 1-substituted-4-(2-methoxyphenyl)-4H-[1,2,4]triazolo [4,3-a] quinazolin-5-ones. 
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Antihistaminic activity 
A series of compounds containing triazolo[4,3-a] 
quinazolines ring system have been evaluated for their in 
vivo antihistaminic activity. Protection against histamine 
induced bronchospasm on conscious guinea pigs method 
was adopted to determine the antihistaminic potential of 
the test compounds. All of them have been found to exhibit 
significant antihistaminic activity (Table 1). Percentage 
protection data showed that all test compounds of the 
series show significant protection in the range of 65- 68%. 
Structure activity relationship (SAR) studies indicated that 
different substituents on the C-1, exerted varied biological 
activity. It has been found that presence of methyl group 
showed better activity over the unsubstituted compounds. 
When chain length increased from methyl to ethyl and 
propyl the activity decreased. Replacement of a proton of 
the methyl group by chloro showed further decrease in 
activity. While the order of activity was methyl > ethyl > 
unsubstituted > propyl > chloromethyl. Among the series, 
4-(2-methoxyphenyl)-1-methyl-[1,2,4]triazolo[4,3-a] 
quinazolin-5(4H)-one (5) was the most potent with the 
percentage protection of 68.67% and it is comparable to 
that of standard chlorpheniramine maleate (percentage 
protection 71.00). As the test compounds could not be 
converted to water soluble form, in vitro evaluation for 
antihistaminic activity could not be performed. 
Sedative-hypnotic activity  
As sedation is one of the major side effects associated with 
antihistamines, the test compounds were also evaluated for 
their sedative potentials. Sedative-hypnotic activity was 
determined by measuring the reduction in motor activity. 
The results of this study (Table 1) showed that almost all 
the test compounds were found to exhibit mild activity 
(less than 10%). Cetirizine and chlorpheniramine maleate 
were used as references, chlorpheneramine showed nearly 
35% of sedation and cetrizine showed 10-13% of sedation. 
Compare to the reference standard choloropheniramine 
maleate, all the test compounds showed lesser sedative 
potential; while compare to ceterizine (non-sedative 
antihistamine) the test compounds showed equipotent 
sedative activity. Hence this series can be developed as 
clinically useful non sedative antihistamines.  
Conclusion 
In summary the synthesis of new series of 1-substituted-4-
(2-methoxyphenyl)-4H-[1,2,4]triazolo [4,3-a] quinazolin-
5-ones has been described. These derivatives have 
exhibited promising antihistaminic activity against 
histamine-induced bronchospasm on conscious guinea pigs 
model. Among the series 1-methyl-4-(2-methoxyphenyl)-
4H-[1,2,4]triazolo[4,3-a] quinazolin-5-one (5) was found 
to be the most active antihistaminic agent, which is 
equipotent (percentage protection of 68.67%) with that of 
the reference standard chlorpheniramine maleate 
(percentage protection 71.00). Interestingly the sedative 
property of compound 5 was found to be negligible (8.1%) 
when compared to chlorpheneramine maleate (34.6%), 
therefore it could serve as a lead molecule for further 








bronchospasm (in Sec) 
% Protection 
Percent CNS Depression 
1 h 2 h 3 h 
4 362.50±4.656** 67.41±0.417** 7.17±0.08** 9.38±0.08** 4.32±0.09** 
5 377.00±4.481** 68.67±0.371** 8.81±0.17** 11.32±0.12** 4.27±0.17** 
6 368.00±3.862** 67.91±0.337** 8.22±0.18** 12.66±0.10** 5.40±0.08** 
7 349.00±3.973** 66.16±0.386** 10.63±0.06** 13.36±0.04** 6.21±0.10** 
8 343.33±4.888** 65.59±0.495** 7.66±0.13** 8.45±0.14** 5.74±0.07** 
 Values were expressed as Mean ± SEM; n=6. Statistical significance: (**p < 0.05) One way ANOVA followed by Dunnett test. 
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